Encouraging Local Control With Pediatric Spatially Fractionated Radiation Therapy.

Authors

Roman O Kowalchuk, Safia K Ahmed, Daiki Hara, Hok Wan Chan Tseung, Peter J Schoettler, Wendy A Allen-Rhoades, Chelsea M Self, Dawn Owen, Michael P Grams, Anita Mahajan, Nadia N Laack

Published in

Advances in radiation oncology. Volume 11. Issue 8. Pages 102069. Epub Jun 23, 2026.

Abstract

Spatially fractionated radiation therapy (SFRT) is a promising treatment involving the delivery of discrete spheres of high-dose radiation, potentially enhancing treatment response. Despite encouraging results for adult patients, no SFRT data exist in pediatric patients.
All pediatric patients receiving radiation therapy from 2019 to 2025 with at least 1 follow-up imaging study were considered. Patient characteristics and outcomes were recorded via institutional review board-approved retrospective chart review.
Five pediatric patients who received SFRT were identified, with a median age of 15.7 years (range, 6.5-17.2 years). Three were alive at last follow-up (median, 13 months; range, 3-18 years). Neither tumor progression nor grade ≥ 2 toxicity was identified at SFRT sites. One recurrent wound infection occurred after enoxaparin sodium injection in the high-dose radiation therapy field. Two patients received upfront SFRT for pelvic osteosarcoma, followed by 74.8 Gy in 34 fractions and 69 Gy in 30 fractions. The treatment volume was over 600 cm³ in both cases, allowing for delivery of 26 and 46 high-dose spheres. Both patients remain alive with primary tumor control; however, both have metastatic disease. Three other cases treated metastatic and/or recurrent disease: Ewing sarcoma, anaplastic ependymoma, and renal cell carcinoma. Sites included chest wall (n = 2), lung (n = 5), and pelvis (n = 1). One patient had 4 courses of SFRT, including 3 small lung volumes < 20 cm³ allowing delivery of 2 to 5 spheres per treatment.
We present one of the first case series of SFRT in pediatric patients, with favorable local control and toxicity results. Further study of SFRT for radioresistant or recurrent tumors is required.

PMID:
42382854
Bibliographic data and abstract were imported from PubMed on 01 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.